How does IBXN.F's PE Ratio compare to its peers?

IBXN.F is expensive based on its Price-To-Earnings Ratio (8.9x) compared to the peer average (5.7x).

How does IBXN.F's PE Ratio compare vs other companies in the US Biotechs Industry?

IBXN.F is good value based on its Price-To-Earnings Ratio (8.9x) compared to the US Biotechs industry average (21.3x).

What is IBXN.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate IBXN.F's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of IBXN.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

IBXN.F ($1) is trading below our estimate of [[fair value]] ($1.05)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

IBXN.F Stock Overview

IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. More details

IBXN.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	5/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 4.6% below our estimate of its fair value

Earnings grew by 187.4% over the past year

Risk Analysis

High level of non-cash earnings

Shares are highly illiquid

Does not have a meaningful market cap ($35M)

My Notes

Capture your thoughts, links and company narrative

IBEX Technologies Inc. Competitors

Precision BioSciences

NasdaqCM:DTIL

US$38.4m

PharmaCyte Biotech

NasdaqCM:PMCB

US$11.2m

CytomX Therapeutics

NasdaqGS:CTMX

US$66.5m

Spero Therapeutics

NasdaqGS:SPRO

US$46.7m

Price History & Performance

Summary of share price highs, lows and changes for IBEX Technologies
Historical stock prices
Current Share Price	CA$1.00
52 Week High	CA$1.10
52 Week Low	CA$0.56
Beta	-0.045
1 Month Change	-5.71%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	256.58%
5 Year Change	699.36%
Change since IPO	960.45%

Recent updates

Shareholder Returns

	IBXN.F	US Biotechs	US Market
7D	-6.5%	0.9%	0.4%
1Y	n/a	-2.1%	23.1%

Return vs Industry: Insufficient data to determine how IBXN.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how IBXN.F performed against the US Market.

Price Volatility

Is IBXN.F's price volatile compared to industry and market?
IBXN.F volatility
IBXN.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.2%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.7%
10% least volatile stocks in US Market	3.2%

Stable Share Price: IBXN.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine IBXN.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1972	n/a	Paul Baehr	www.ibex.ca

IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research.

IBEX Technologies Inc. Fundamentals Summary

How do IBEX Technologies's earnings and revenue compare to its market cap?
IBXN.F fundamental statistics
Market cap	US$25.98m
Earnings (TTM)	US$2.93m
Revenue (TTM)	US$5.89m

8.9x

P/E Ratio

4.4x

P/S Ratio

Is IBXN.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IBXN.F income statement (TTM)
Revenue	CA$8.00m
Cost of Revenue	CA$2.23m
Gross Profit	CA$5.77m
Other Expenses	CA$1.79m
Earnings	CA$3.98m

Last Reported Earnings

Jan 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.16
Gross Margin	72.11%
Net Profit Margin	49.70%
Debt/Equity Ratio	0%

How did IBXN.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/04/08 20:39
End of Day Share Price	2024/04/08 00:00
Earnings	2024/01/31
Annual Earnings	2023/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

IBEX Technologies Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution